Dosimertinib mesylate - Genuine Biotech
Alternative Names: 90-1408; Dositinib - Genuine BiotechLatest Information Update: 06 Dec 2025
At a glance
- Originator Genuine Biotech
- Class Acrylamides; Amines; Aniline compounds; Anisoles; Antineoplastics; Dimethylamines; Ethylenediamines; Indoles; Methylamines; Organic deuterium compounds; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 06 Dec 2025 Chemical structure information added.
- 27 Nov 2025 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (PO) (NCT07362940)
- 30 Sep 2025 Genuine Biotech has patent protection for Dositinib in USA